Congratulations To

SUNSHINE PHARMA (Stock Code: 6887.HK)

On The Successful IPO On The Main board Of The HKEX!

COMPANY PROFILE

Sunshine Lake Pharma Co Ltd is a China-based company principally engaged in research and development, production and commercialization of pharmaceutical products. The Company focuses on innovative drugs and is also involved in modified new drugs, generic drugs and biosimilars. The Company’s anti-infective products include Kewei (oseltamivir phosphate), for the treatment of influenza (in particular, Type A and Type B influenza viruses), Dongweien (emitasvir phosphate), for the treatment of hepatitis C, and generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin and Moxifloxacin Hydrochloride. The Company’s commercialized chronic disease treatment drugs primarily focus on the treatment of diabetes, hyperuricemia, hypertension and stomach acid related disease, including insulin products and generic drugs. The Company also focuses on therapeutic area of oncology.

(Source：http://www.hkex.com.hk/）

CR SWCS Team is honoured to serve as SUNSHINE PHARMA’s Company Secretary,

committed to ensuring governance, compliance, and sustained growth.